BiotechTube

desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vasomotor Symptoms

Conditions

Vasomotor Symptoms

Trial Timeline

Dec 1, 2006 → Jan 1, 2008

NCT ID
NCT00401245

About desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release

desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release is a phase 3 stage product being developed by Pfizer for Vasomotor Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT00401245. Target conditions include Vasomotor Symptoms.

What happened to similar drugs?

1 of 13 similar drugs in Vasomotor Symptoms were approved

Approved (1) Terminated (0) Active (12)
🔄fezolinetant + placeboAstellas PharmaPhase 3
✅17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)PfizerApproved
🔄DVS-233 SRPfizerPhase 3
🔄Bazedoxifene/Conjugated EstrogenPfizerPhase 3
🔄desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3
🔄Elinzanetant (BAY3427080) + PlaceboBayerPhase 3
🔄Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mgBayerPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00401245Phase 3Completed

Competing Products

20 competing products in Vasomotor Symptoms

See all competitors
ProductCompanyStageHype Score
fezolinetant + placeboAstellas PharmaPhase 3
40
Raloxifene + medroxyprogesterone acetate + estrogen + 17 beta estradiolEli LillyPhase 2
35
esomeprazole + placeboAstraZenecaPre-clinical
26
MK-6913 + 17-β estradiol + Placebo to MK-6913 + Placebo to 17-β estradiol + MK-6913 25 mgMerckPhase 2
27
Erenumab + PlaceboAmgenPhase 1
29
17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)PfizerApproved
43
DVS-233 SRPfizerPhase 3
40
Bazedoxifene/Conjugated EstrogenPfizerPhase 3
40
desvenlafaxine succinate sustained release (DVS SR)PfizerPhase 1
29
desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3
40
Treatment A + Treatment B + Treatment CBayerPhase 1
26
Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
26
Elinzanetant (BAY3427080) + PlaceboBayerPhase 3
41
Elinzanetant (BAY3427080) treatment A + Elinzanetant (BAY3427080) treatment BBayerPhase 1
26
Elinzanetant (BAY3427080)BayerPhase 1
26
Moxifloxacin + Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
26
Elinzanetant (BAY3427080) + Dabigatran etexilateBayerPhase 1
26
Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mgBayerPhase 3
37
BAY3427080BayerPhase 1
26
Elinzanetant (BAY3427080) + RosuvastatinBayerPhase 1
26